Chronic exposure to SCO-267, an allosteric GPR40 full agonist, is effective in improving glycemic control in rats

Ryokichi Koyama; Mitsugi Ookawara; Masanori Watanabe; Yusuke Moritoh

doi:10.1124/molpharm.120.000168

Article Information

MOLPHARM-AR-2020-000168

DOI

https://doi.org/10.1124/molpharm.120.000168

PubMed

33547250

Published By

American Society for Pharmacology and Experimental Therapeutics

Print ISSN

0026-895X

Online ISSN

1521-0111

History

Published online February 5, 2021.

© 2020 The Authors. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited and is not used for commercial purposes.

Author Information

Ryokichi Koyama1,
Mitsugi Ookawara1,
Masanori Watanabe1, and
Yusuke Moritoh1,*

¹SCOHIA PHARMA, Inc., Japan

↵* Corresponding Author:
Yusuke Moritoh, SCOHIA PHARMA, Inc., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 2518555, Japan. E-mail: yusuke.moritoh{at}scohia.com